Entering text into the input field will update the search result below

CureVac COVID-19 vaccine’s subpar efficacy: scientists explore reasons

Jun. 19, 2021 10:17 PM ETCureVac N.V. (CVAC) StockPFE, MRNA, BNTX, CVACBy: Dulan Lokuwithana, SA News Editor25 Comments

Elon Musk Announces Visit To Germany
Christian Kaspar-Bartke/Getty Images News

  • This week, CureVac (NASDAQ:CVAC) shocked investors and scientists alike by announcing a drastically low efficacy rate for its messenger-RNA-based COVID-19 shot from a large global trial.
  • Compared to the ~95% efficacy rate shown by established mRNA-based vaccines from Pfizer

Recommended For You

About CVAC Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
CVAC--
CureVac N.V.